BSC Business/EH

1
BSC Business/EHS Overview

• More than 25 Years Advancingthe Practice of
  Less-Invasive Medicine

2
Boston Scientific is a global, multi-billion
dollar company focused on less-invasive medical
devices and procedures
Boston Scientific Corporation Profile
Compound Annual Growth Rate
3
Boston Scientific products help treat a broad
range of medical conditions throughout the body
4
Boston Scientific offers market leading
technologies for many of the most prevalent and
debilitating diseases
DISEASE PREVALENCE BOSTON SCIENTIFIC FACTS
Cardiovascular Disease accounts for more than 40 percent of all deaths in U.S. BSC interventional cardiology products are used in about one million procedures annually
Neurovascular Disease is one of the leading causes of death in the U.S. BSCs is a leading supplier of products for neurovascular intervention with less-invasive technologies under investigation for treating intra-cranial atherosclerotic and carotid artery disease
Abdominal Aortic Aneurysm (AAA) more than one million Americans have AAA a significant portion can be treated with early detection BSC is a worldwide leader of surgical aortic repair and currently has less-invasive technology in development
Peripheral Vascular Disease afflicts approximately 3.7 million people in the U.S. and is a common condition in Americans 65 and older BSC is a leader in peripheral vascular treatment
Heart Arrhythmias as many as two million Americans are living with atrial fibrillation, with about 160,000 new cases each year, increasing patients chances of stroke by five times BSCs cardiac ablation procedures are used in 80 percent of the electrophysiology labs in the U.S.
Incontinence affects approximately 13 million adults in the U.S., occurring in women twice as often as men More than 20,000 women per year are treated with BSCs urinary incontinence products
Kidney Stones more than one million Americans are treated for kidney stones each year Worldwide, nearly 350,000 patients annually are treated with BSCs kidney stone-related devices
Uterine Fibroids develop in 25 percent of all women at some point in their lives, and nearly six million cases are left untreated BSCs Uterine fibroid embolization is a growing alternative treatment, with gt13,000 procedures performed in 2004
Pancreaticobiliary Disease (gallstones) more than 500,000 Americans undergo gallbladder surgery each year BSC Endoscopy is a market leader in endoscopic devices to treat gallstones
5
Over 25 years of Innovation has led to a broad
portfolio of more than 15,000 products
Sampling of Boston Scientifics Product Portfolio
6
Guidant AcquisitionRedefining Bold

• Consistent with BSC Strategy
• Long-term interest in CRM
• DES Alternative
• Diversification and Growth

7
Boston Scientific is organized into three major
groups and eleven distinct businesses
2004 Revenues 5.6 Billion
Groups
Businesses
Cardiovascular 04 Revenue 4.480B Company Total 80 Endosurgery 04 Revenue 1.088B Company Total 19 Neuromodulation 04 Revenue 46M Company Total 1
8
Boston Scientific has evolved from early pioneer
to industry leader
Global Leadership in Interventional Medicine
6,283
Revenue (000)
Phase IV Next Chapter
Phase II Strategic Mass (Via Acquisitions)
Phase I Less-Invasive MedicinePioneer/Leader
Phase III Stent Integration DES Leadership
9
We Achieve Global Leadership in our Key Markets
10
BSC has made significant internal RD investments
to champion new ideas and products into new
markets
New Product Development Delivering whats next.TM
11
The result of our Hybrid Model is a Robust
Product Pipeline
Product Priorities that will shape our future
12
What Defines the BSC EHS Program

• Focus and clarity
• Measuring our contribution we put points on the
  board
• Ruthless prioritization we drive what matters
• Compliance as a given integrity in our actions
• Developing integrated business-driven solutions

13
Highly Valued Aspects

• Environmental Management Systems
• Injury Incidence and Severity Rates
• GHG Emissions/Energy Efficiency
• Risk
• Compliance

14
TRIR
15
LWR
16
Global Ergonomics Initiative( a.k.a. ergo-lean)

• Premise Wasted Motion/Posture, Frequency and
  Force Ergonomic Risk and Inefficiencies
• Approach Provide Fast and Quantitative Same as
  Same Tools Across Sites
• Integrating into Lean Manufacturing

17
Results Summary

• Risk Reductions Ranging Between 25-80
• New York Forecasting 670 K Income Increase Using
  FORM (3X) Based Upon Measured Cycle Time
• Costa Rica Forecasting 5.1 MM Income Increase
  using FORM (8X) Based Upon Measured Output
• Tullamore Projecting 27 Cycle Time Improvement
  with 8 FTEs Freed, 20 Reduction in Floor Space
• We Put Points on the Board

18
Why ISO-14001 Certification

• Our Most Effective Response to Environmental
  Tender Requests Currently at 70 VOP
• Focused Aspects Analysis Will Drive the Correct
  Environmental Elements
• Supports BSC Environmental Program and External
  Perception

19
Expanding Environmental program

• Desire to Have BSC Recognized as an Environmental
  Leader
• Are Examining all BSC Environmental Aspects
• Premise is Based on Triple Win Elements

20
Choosing our Business Partners

• BSC is a performance based company, Delivering
  whats next
• Partners need to be performance, not process,
  based
• We expect the best people
• We look for team culture, with the ability to
  listen, and the courage to lead
• We expect fair pricing
• We watch accountability

21
Thank You